Organon, a global healthcare company with a focus on women’s health, entered into an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe. Emgality, a humanized monoclonal antibody calcitonin gene-related peptide (CGRP) antagonist, is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. RAYVOW is a first-in-class serotonin 5-HT1F recep...